Roth MKM Maintains Buy on Panbela Therapeutics, Adjusts Price Target To $25
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jonathan Aschoff has maintained a Buy rating on Panbela Therapeutics (NASDAQ:PBLA) and adjusted the price target to $25 from $500.
February 05, 2024 | 7:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roth MKM maintains a Buy rating on Panbela Therapeutics, adjusting the price target to $25 from $500.
The maintenance of a Buy rating by a reputable analyst suggests a positive outlook on the stock, potentially encouraging investor confidence and demand. The significant adjustment in the price target, however, may raise questions about previous valuations but still indicates a strong belief in the company's value proposition.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100